We are international

Myeloma Minute - November 29, 2007
Welcome to the IMF's Myeloma Minute
News about myeloma treatment, research, support and the myeloma community
from the International Myeloma Foundation.


Important Correction
There was an error in last week's Minute concerning the ECOG E1A05 trial. The corrected description of the trial follows:

  • The Eastern Cooperative Oncology Group's E1A05

    This is a randomized study using Bortezomib (also called Velcade) in combination with a steroid, dexamethasone (also called Decadron), with and without Lenolidamide (also called Revlimid.) Patients are elegible to participate if they have completed a dexamethasone-based treatment as their first treatment for myeloma and are not going on to a stem cell transplant at this time.

    Patients will be randomly assigned to one of two groups:

    * Group 1 will receive Bortezomib with dexamethasone

    * Group 2 will receive Lenalidomide with dexamethasone and Bortezomib

    All patients will participate in a Quality of Life Survey during treatment and after treatment. All patients will be followed for up to seven years to assess the long-term effects of the study treatements.

  • List of Institutions participating in this trial.

Researchers at UAMS Transfer Immune Response to Myeloma Patient; Study Points to Potential Cancer Vaccination
In the study, a healthy individual was immunized with a cancer protein that can kick start the body’s immune system to kill cancer cells. The cancer-killing antibodies produced by the healthy patient’s immune system were then transferred via stem cell transplant to her twin sister, who had been diagnosed with multiple myeloma, in conjunction with chemotherapy. The same immune response was subsequently observed in the patient, who remains in remission nearly three years after the transplant. (from Newswise)

Dr. Boccadoro
The IMF is proud to announce the VI Annual Robert A. Kyle Lifetime Achievement Award Dinner Honoring Dr. Mario Boccadoro on February 6, 2008
The dinner will be held in the beautiful Palazzina di Caccia Stupinigi in Torino.

Cancer Risk: Understanding the Puzzle
A new interactive site about cancer risk from the National Cancer Institute. It will help you make informed decisions about how you can lower your risk.

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Three large, randomized Phase III trials of VELCADE in front-line multiple myeloma to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting (from CNN Money)

Study Assays Marrow Transplant Troubles
Bone marrow transplants are one of cancer care's striking successes, but they have a dark side: graft-versus-host disease, or GVHD. The last decade has brought little progress in battling it, and last month brought another blow, as the Food and Drug Administration rejected the new drug closest to market. (from the Associated Press by way of WTOP News)

Nereus Pharmaceuticals to present preclinical study results involving NPI-0052 at ASH
Two oral presentations and two posters will highlight the novel mechanism, high potency and synergistic anti-tumor activity of the small molecule proteasome inhibitor NPI-0052 in combination with bortezomib (Velcade®, Millennium Pharmaceuticals) in several tumor models for multiple myeloma, Waldenstrom's macroglobulinemia and B-non-Hodgkin's lymphoma. (from Business Wire)

Drug combination effective against multiple myeloma
In the study conducted at 44 centers in the United States and Canada, 353 patients with myeloma received either a combination of lenalidomide (Revlimid®) and the steroid dexamethasone or dexamethasone plus a placebo. "Those taking the lenalidomide combination had a median time to disease progression of 11.1 months compared with 4.7 months in the placebo-dexamethasone group and an improved median overall survival time of 29.6 months compared with 20.2 months," says lead author Donna Weber, M.D., of M. D. Anderson Cancer Center. (from HULIQ.com)
(See article abstract below.)

Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Patients with Multiple Myeloma
Human trial with GRN163L follows preclinical data showing single-agent activity against multiple myeloma cancer stem cells and cancerous plasma cells (from Business Wire)

Even if you missed Cyber Monday, the heaviest online shopping day, it is not too late to buy your holiday presents and help the IMF at the same time. Just use the special links (like the one for Amazon.com) on the Shop for the IMF page to give to your loved ones and the myeloma community as well. And so, with apologies to The Sound of Music, to the tune of My Favorite Things:

Buy polos from Lands End and music from Walmart,
Tickets from Delta...It feels good to do your part.
Make a visit to Macy's to buy her a ring.
Help IMF with your favorite things!

Also check out the IMF's Holiday Boutique for more gift ideas.

(IMF Scientific Advisors are marked with an *)
  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
    Donna M. Weber, M.D., Christine Chen, M.D., Ruben Niesvizky, M.D., Michael Wang, M.D., Andrew Belch, M.D., Edward A. Stadtmauer, M.D., David Siegel, M.D., Ivan Borrello, M.D., S. Vincent Rajkumar, M.D., Asher Alban Chanan-Khan, M.D., Sagar Lonial, M.D., Zhinuan Yu, Ph.D., John Patin, M.S., Marta Olesnyckyj, R.N., Jerome B. Zeldis, M.D., Ph.D., Robert D. Knight, M.D., for the Multiple Myeloma (009) Study Investigators

    New England Journal of Medicine published 21 November 2007, Volume 357:2133-2142
  • Etanercept plus methylprednisolone as initial therapy for acute GVHD
    John E Levine, Sophie Paczesny, Shin Mineishi, Thomas Braun, Sung W Choi, Raymond J Hutchinson, Dawn Jones, Yasser Khaled, Carrie L Kitko, Daniel Bickley, Oleg Krijanovski, Pavan Reddy, Gregory Yanik, and James L.M. Ferrara
    Blood published 27 November 2007, 10.1182/blood-2007-09-112987

  • VELCADE® trials

  • THALOMID® trials

  • REVLIMID® trials

  • DOXIL® trials

  • Phase I/II trial to determine the safety and maximum tolerated dose of GRN163L, a telomerase inhibitor,  when administered intravenously in patients with multiple myeloma who have failed at least two courses of standard chemotherapy.  Lead investigator is Dr. Asher  Chanan-Kahn at Roswell Park Cancer Institute in Buffalo, NY.

If you would like more information about any clinical trial, you can call the IMF Hotline at 800-452-CURE. The Myeloma Matrix has a current list of all myeloma trials from pre-clinical to recently FDA approved. If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find EmergingMed, with whom the IMF has entered into a partnership to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.

NOTE: The dates for the Atlanta (Buckhead) Patient & Family Seminar are changing. We will post the new date as soon as it is set. If you have already reserved your place at the seminar, you will be contacted to reconfirm your reservation.
Little Rock Regional Community Workshop - Little Rock, Arkansas
December 1, 2007
Planning for Treatment With or Without Transplant: Balancing Efficacy, Toxicity, and Quality of Life for the Patient with Multiple Myeloma
Save the Date! Friday Satellite Symposium on December 7, 2007 preceding the 49th ASH Annual Meeting
St. Louis Regional Community Workshop - St. Louis, Missouri
December 15, 2007
Seattle Patient & Family Seminar - Seattle, Washington
June 27-28, 2008
San Diego Patient & Family Seminar - San Diego, California
August 22-23, 2008

The IMF's comprehensive "How-to-FUNdraise" guide is what you need if you're thinking about fundraising in your community but don't know where to start. The guide contains the A - Z of fundraising ideas--like running in a local marathon and asking for donations per mile for myeloma; having a holiday party, where you charge a cover and hold a raffle; asking your local supermarket to donate wine and cheese, then selling tickets and having a cocktail party--as well as tips and guidelines for success. Check out the FUNdraisers below and show your support by donating to their effort online:

Multiple Myeloma Night with the Philadelphia Phantoms - Philadelphia, Pennsylvania
December 14, 2007

An Evening of Believing - Lewisville, Texas
February 23, 2008
Commissions for Chris: A Campaign to Honor Chris Hollyer
Jo Marie Gray is donating her new-client commissions from the sale of Arbonne Cosmetics to the Chris Hollyer Research Fund at the IMF.
Cents for Cells
Beth Morgan is helping the IMF by raising a penny for each stem cell that will be collected for her BMT. She has dedicated Cents for Cells to the memory of Chris Hollyer.
Clyde's Ride for the Cure
Clyde is riding his bicycle to support the work of the IMF. "I say, 'until there is a cure I ride for the IMF.'"
Miles for Myeloma
Larry Bartolin is a six-year survivor of multiple myeloma, and is riding his motorcycle to raise funds and public awareness.
Losing Weight to Gain Awareness
Debi is losing weight to raise money for research and the awareness programs of the IMF.

Shopping in the IMF Holiday Boutique is the perfect opportunity to help your gifts give twice - once to the recipient, and once to the myeloma community through the IMF.
As a non-profit organization, the IMF is completely dependent on the support of our members. Tax-deductible donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. And you can order beautiful tribute cards to send out to your friends and family every time you make a donation in their honor to the IMF.We sincerely thank you for your support.
Shop for the IMF
Shop with the leading merchants on the Internet, receive the same price as anyone else visiting their sites, and support the IMF at the same time!
Imperial Jewels of China, 2008
Cruise the mighty Yangtze river, and marvel at the mystical scenery of Asia's most revered and dramatic natural attractions.
Read the latest issue of the IMF Travel Advantage newsletter for this and other fabulous trips. Great prices and you are helping the IMF with every vacation.
Difford Bracelets Multiple Myeloma Awareness Bracelets
Beautiful custom made jewelry to honor those who have joined the struggle against multiple myeloma.

Caregiver Daily Journal

Caregiver Daily Journal
If you know a caregiver, the IMF's own Sylvia Baca has written a journal to help document the daily care they give their loved one. It's $25, with all profits going to support the programs of the IMF..

Sarah Klein's Bracelets

Sterling Bracelets by Sarah Klein
Sarah Klein's father, Benson, was diagnosed with myeloma in 1998, and has been in remission for 8 years.
Sarah wants to give back to the IMF in her own creative way and has designed two special bracelets made up of semi-precious healing stones. A portion of the proceeds from the sale of these bracelets is being donated to the IMF.

IMF Christmas Cards With Original Jr. IMFer Art
Ten cards per box, five of each style.
Inside card reads: Warmest wishes for peace, love, health and happiness this Christmas and throughout the year.

Ribbon of Hope Ornament
Whether hanging on a holiday tree, a wall, or any other creative place you can think of, the IMF's Ribbon of Hope ornament will bring a message of hope to anyone you give it to.
Multiple Colors for Multiple Myeloma Keychains and Earrings
Bring rainbows of happiness, color and light into your loved ones' lives with an IMF keychain or Swarovski crystal earrings.

Arbonne Cosmetics
Jo Marie Gray is donating her new-client commissions from the sale of Arbonne Cosmetics to the Chris Hollyer Research Fund at the IMF.
IMF Logo Items
Let the world know that you support the groundbreaking research and innovative patient support programs of the IMF with a hat or shirt or bracelets!
See more exciting ways to help the IMF continue its important work in education, support and research.


Mensajero del Mieloma
La IMF les envía información sobre el mieloma en español a todos los pacientes, familiares e interesados. Para suscribirse al correo electrónico (enviamos cuatro ejemplares al año), por favor, mande su dirección a
mensajero@myeloma.org. ¡Gracias!


International Staging System

A tool to help understand the current status of the disease and the questions you should be asking.

Check out HealthTalk's Multiple Myeloma Education Network and Andrew Schorr's Patient Power.

Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.

Sign up for a FREE Subscription to Myeloma Today, the
Official Newsletter of the IMF!

Many thanks to the supporters of The Myeloma Minute:
Celgene Corporation, Kyphon, Millennium Pharmaceuticals, Ortho Biotech, and The Binding Site.
Please call the hotline (800) 452-CURE (800-452-2873) or email TheIMF@myeloma.org if you have any questions.
Copyright 2002-2007. International Myeloma Foundation. All Rights Reserved.

 related articles